GLP-1 use nearly doubled in 3 years among patients with MASH, compensated cirrhosis

Nearly 1 in 5 people with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis were prescribed a GLP-1 receptor agonist in the past decade, according to a poster presented at The Liver Meeting.GLP-1 use is growing every year and expanding to treat a wide range of conditions beyond obesity and diabetes, including noncirrhotic MASH. However, no treatments have been approved